Marion Ortner1, Alexander Kurz2, Panagiotis Alexopoulos2, Florian Auer3, Janine Diehl-Schmid2, Alexander Drzezga4, Stefan Förster5, Hans Förstl2, Robert Perneczky6, Christian Sorg2, Behrooz H Yousefi7, Timo Grimmer2. 1. Department of Psychiatry and Psychotherapy, Klinikum rechts der Isar der Technischen Universität München, Munich, Germany. Electronic address: marion.ortner@lrz.tum.de. 2. Department of Psychiatry and Psychotherapy, Klinikum rechts der Isar der Technischen Universität München, Munich, Germany. 3. Department Diagnostic and Interventional Neuroradiology, Klinikum rechts der Isar der Technischen Universität München, Munich, Germany. 4. Department of Nuclear Medicine, University Köln, Cologne, Germany. 5. Department Nuclear Medicine, Klinikum rechts der Isar der Technischen Universität München, Munich, Germany. 6. Department of Psychiatry and Psychotherapy, Klinikum rechts der Isar der Technischen Universität München, Munich, Germany; Neuroepidemiology and Ageing Research Unit, School of Public Health, Faculty of Medicine, The Imperial College of Science, Technology, and Medicine, London; West London Cognitive Disorders Treatment and Research Unit, West London Mental Health Trust, London, United Kingdom. 7. Pharmaceutical Radiochemistry, Faculties of Chemistry and Medicine, Technische Universität München, Garching, Germany.
Abstract
BACKGROUND: There is controversy concerning whether Alzheimer's disease (AD) with early onset is distinct from AD with late onset with regard to amyloid pathology and neuronal metabolic deficit. We hypothesized that compared with patients with early-onset AD, patients with late-onset AD have more comorbid small vessel disease (SVD) contributing to clinical severity, whereas there are no differences in amyloid pathology and neuronal metabolic deficit. METHODS: The study included two groups of patients with probable AD dementia with evidence of the AD pathophysiologic process: 24 patients with age at onset <60 years old and 36 patients with age at onset >70 years old. Amyloid deposition was assessed using carbon-11-labeled Pittsburgh compound B positron emission tomography, comorbid SVD was assessed using magnetic resonance imaging, and neuronal metabolic deficit was assessed using fluorodeoxyglucose positron emission tomography. Group differences of global and regional distribution of pathology were explored using region of interest and voxel-based analyses, respectively, carefully controlling for the influence of dementia severity, apolipoprotein E genotype, and in particular SVD. The pattern of cognitive impairment was determined using z scores of the subtests of the Consortium to Establish a Registry for Alzheimer's Disease Neuropsychological Assessment Battery. RESULTS: Patients with late-onset AD showed a significantly greater amount of SVD. No statistically significant differences in global or regional amyloid deposition or neuronal metabolic deficit between the two groups were revealed. However, when not controlling for SVD, subtle differences in fluorodeoxyglucose uptake between early-onset AD and late-onset AD groups were detectable. There were no significant differences regarding cognitive functioning. CONCLUSIONS: Age at onset does not influence amyloid deposition or neuronal metabolic deficit in AD. The greater extent of SVD in late-onset AD influences the association between neuronal metabolic deficit and clinical symptoms.
BACKGROUND: There is controversy concerning whether Alzheimer's disease (AD) with early onset is distinct from AD with late onset with regard to amyloid pathology and neuronal metabolic deficit. We hypothesized that compared with patients with early-onset AD, patients with late-onset AD have more comorbid small vessel disease (SVD) contributing to clinical severity, whereas there are no differences in amyloid pathology and neuronal metabolic deficit. METHODS: The study included two groups of patients with probable AD dementia with evidence of the AD pathophysiologic process: 24 patients with age at onset <60 years old and 36 patients with age at onset >70 years old. Amyloid deposition was assessed using carbon-11-labeled Pittsburgh compound B positron emission tomography, comorbid SVD was assessed using magnetic resonance imaging, and neuronal metabolic deficit was assessed using fluorodeoxyglucose positron emission tomography. Group differences of global and regional distribution of pathology were explored using region of interest and voxel-based analyses, respectively, carefully controlling for the influence of dementia severity, apolipoprotein E genotype, and in particular SVD. The pattern of cognitive impairment was determined using z scores of the subtests of the Consortium to Establish a Registry for Alzheimer's Disease Neuropsychological Assessment Battery. RESULTS:Patients with late-onset AD showed a significantly greater amount of SVD. No statistically significant differences in global or regional amyloid deposition or neuronal metabolic deficit between the two groups were revealed. However, when not controlling for SVD, subtle differences in fluorodeoxyglucose uptake between early-onset AD and late-onset AD groups were detectable. There were no significant differences regarding cognitive functioning. CONCLUSIONS: Age at onset does not influence amyloid deposition or neuronal metabolic deficit in AD. The greater extent of SVD in late-onset AD influences the association between neuronal metabolic deficit and clinical symptoms.
Authors: Walter Swardfager; Hugo Cogo-Moreira; Mario Masellis; Joel Ramirez; Nathan Herrmann; Jodi D Edwards; Mahwesh Saleem; Parco Chan; Di Yu; Sean M Nestor; Christopher J M Scott; Melissa F Holmes; Demetrios J Sahlas; Alexander Kiss; Paul I Oh; Stephen C Strother; Fuqiang Gao; Bojana Stefanovic; Julia Keith; Sean Symons; Richard H Swartz; Krista L Lanctôt; Donald T Stuss; Sandra E Black Journal: Neurology Date: 2018-01-26 Impact factor: 9.910
Authors: Alexander N W Taylor; Lana Kambeitz-Ilankovic; Benno Gesierich; Lee Simon-Vermot; Nicolai Franzmeier; Miguel Á Araque Caballero; Sophia Müller; Liu Hesheng; Birgit Ertl-Wagner; Katharina Bürger; Michael W Weiner; Martin Dichgans; Marco Duering; Michael Ewers Journal: Alzheimers Dement Date: 2016-07-16 Impact factor: 21.566
Authors: A Wallin; E Kapaki; M Boban; S Engelborghs; D M Hermann; B Huisa; M Jonsson; M G Kramberger; L Lossi; B Malojcic; S Mehrabian; A Merighi; E B Mukaetova-Ladinska; G P Paraskevas; B O Popescu; R Ravid; L Traykov; G Tsivgoulis; G Weinstein; A Korczyn; M Bjerke; G Rosenberg Journal: BMC Neurol Date: 2017-05-23 Impact factor: 2.474
Authors: Marion Ortner; Marion Stange; Heike Schneider; Charlotte Schroeder; Katharina Buerger; Claudia Müller; Bianca Dorn; Oliver Goldhardt; Janine Diehl-Schmid; Hans Förstl; Werner Steimer; Timo Grimmer Journal: Front Pharmacol Date: 2020-05-21 Impact factor: 5.810
Authors: Wha Jin Lee; Cindy W Yoon; Sung-Woo Kim; Hye Jin Jeong; Seongho Seo; Duk L Na; Young Noh; Joon-Kyung Seong Journal: Front Neurosci Date: 2021-02-16 Impact factor: 4.677
Authors: Denise Visser; Sander C J Verfaillie; Emma E Wolters; Emma M Coomans; Tessa Timmers; Hayel Tuncel; Ronald Boellaard; Sandeep S V Golla; Albert D Windhorst; Philip Scheltens; Wiesje M van der Flier; Bart N M van Berckel; Rik Ossenkoppele Journal: Eur J Nucl Med Mol Imaging Date: 2022-01-08 Impact factor: 10.057
Authors: Marion Ortner; René Drost; Dennis Hedderich; Oliver Goldhardt; Felix Müller-Sarnowski; Janine Diehl-Schmid; Hans Förstl; Igor Yakushev; Timo Grimmer Journal: BMC Neurol Date: 2019-10-31 Impact factor: 2.474
Authors: Timo Grimmer; Werner Steimer; Marion Ortner; Marion Stange; Heike Schneider; Charlotte Schröder; Katharina Buerger; Claudia Müller; Felix Müller-Sarnowski; Janine Diehl-Schmid; Hans Förstl Journal: Drug Des Devel Ther Date: 2020-08-11 Impact factor: 4.162